Health Canada is warning of serious health risks from injecting the drugs
It means that the product is intended for: Laboratory studies Analysis Research work Experimental procedures It does not mean that the product is approved for use as medication
Cagrilintide Dose Escalation Studies Phase 2 trials evaluated multiple cagrilintide doses to identify the optimal balance between efficacy and tolerability: 0.3 mg weekly Minimal efficacy, excellent tolerability 0.6 mg weekly Moderate effects, good tolerability 1.2 mg weekly Strong efficacy, acceptable side effects 2.4 mg weekly Optimal efficacy-tolerability balance 4.5 mg weekly Excessive GI side effects outweighed benefits The 2.4 mg weekly dose emerged as the standard in phase 3 trials, providing substantial metabolic benefits while maintaining an acceptable side effect profile[6]
The short GHK-Cu half life leaves zero room for error
Althaus, B.U., Staub, J.J., Ryff-De Lche, A., Oberhnsli, A
Genomics 29 , 773776 (1995)